Home › Compare › KTRA vs QYLD

KTRA vs QYLD: Dividend Comparison 2026

KTRA yields 928.51% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KTRA wins by $9.224768444729638e+22M in total portfolio value
10 years
KTRA
KTRA
● Live price
928.51%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.224768444729638e+22M
Annual income
$92,228,602,655,528,430,000,000,000,000.00
Full KTRA calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — KTRA vs QYLD

📍 KTRA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKTRAQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KTRA + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
KTRA pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KTRA
Annual income on $10K today (after 15% tax)
$78,922.93/yr
After 10yr DRIP, annual income (after tax)
$78,394,312,257,199,170,000,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, KTRA beats the other by $78,394,312,257,199,170,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KTRA + QYLD for your $10,000?

KTRA: 50%QYLD: 50%
100% QYLD50/50100% KTRA
Portfolio after 10yr
$4.612384222364819e+22M
Annual income
$46,114,301,327,764,220,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KTRA right now

KTRA
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
-7.7
Piotroski
1/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KTRA buys
0
QYLD buys
0
No recent congressional trades found for KTRA or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKTRAQYLD
Forward yield928.51% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100% ✓0%
Portfolio after 10y$9.224768444729638e+22M$25.4K ✓
Annual income after 10y$92,228,602,655,528,430,000,000,000,000.00 ✓$5,659.31
Total dividends collected$9.22464356544689e+22M$27.1K ✓
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: KTRA vs QYLD ($10,000, DRIP)

YearKTRA PortfolioKTRA Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$196,401$185,701.02$10,352$1,192.36+$186.0K → KTRA
2$7,027,321$6,817,172.01$10,830$1,347.57+$7.02M → KTRA
3$463,447,509$455,928,275.47$11,460$1,539.07+$463.44M → KTRA
4$56,698,112,446$56,202,223,611.72$12,275$1,777.84+$56698.10M → KTRA
5$12,912,579,631,755$12,851,912,651,437.11$13,323$2,078.95+$12912579.62M → KTRA
6$5,484,711,654,366,623$5,470,895,194,160,645.00$14,667$2,463.34+$5484711654.35M → KTRA
7$4,349,424,397,994,440,700$4,343,555,756,524,268,500.00$16,396$2,960.57+$4349424397994.42M → KTRA
8$6,442,930,094,194,810,000,000$6,438,276,210,088,955,000,000.00$18,631$3,612.97+$6442930094194810.00M → KTRA
9$17,833,450,250,405,050,000,000,000$17,826,556,315,204,260,000,000,000.00$21,548$4,482.15+$17833450250405050368.00M → KTRA
10$92,247,684,447,296,380,000,000,000,000$92,228,602,655,528,430,000,000,000,000.00$25,398$5,659.31+$9.224768444729638e+22M → KTRA

KTRA vs QYLD: Complete Analysis 2026

KTRA — Stock

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Full KTRA Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this KTRA vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KTRA vs SCHDKTRA vs JEPIKTRA vs OKTRA vs KOKTRA vs MAINKTRA vs XYLDKTRA vs JEPQKTRA vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.